Uncategorized

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance

We have repeatedly heard the following statements about multi-drug resistant HIV (MDR-HIV) patients in a host of meetings on treatment access and HIV research: “These patients no longer exist – they’re either dead or have responded to the latest ARVs”; “Only patients who do not adhere to their HIV regimens have MDR-HIV”; and “Our clinic cannot provide expanded access programs (EAPs) due …

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance Read More »

HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker

From Natap.org HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker3rd International Workshop on HIV and Aging, November 5-6, 2012, Baltimore Mark Mascolini HIV infection, active HCV infection, and income below $15,000 a year independently predicted shorter telomere length in a study of 229 HIV-positive people and 166 HIV-negative people in …

HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker Read More »

SIGN PETITION: Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW!

Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW! The most effective new therapy ever discovered for the treatment of hepatitis C will never see the light of day unless we are able to convince big pharma giant Gilead Sciences to move forward at once with this development. This treatment combines Bristol-Myers Squibb drug daclatasvir and …

SIGN PETITION: Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW! Read More »

Of the 1.1 million Americans living with HIV, only 25 percent are virally suppressed.

 Of the 1.1 million Americans living with HIV, only 25 percent are virally suppressed. This is worrisome data that reflects how the world’s biggest super power still has problems getting HIV infected people treated even with access to more than 24 HIV medications and federally funded programs https://www.thebody.com/content/69009/hiv-in-the-united-states-the-stages-of-care.html?ic=700100

Novel Cell and Gene Therapies for HIV

Although the development of cell-based and gene transfer therapies has been slow, progress in a number of areas is evident. Advances in the fields of gene-targeting strategies, T-cell-based approaches, and HSCs have been encouraging, and a series of ongoing and planned trials to establish proof of concept for strategies that could lead to successful cell …

Novel Cell and Gene Therapies for HIV Read More »

Johns Hopkins study suggests the commonly prescribed anti-retroviral drug efavirenz attacks brain cells

Popular HIV drug may cause memory declines Johns Hopkins study suggests the commonly prescribed anti-retroviral drug efavirenz attacks brain cells The way the body metabolizes a commonly prescribed anti-retroviral drug that is used long term by patients infected with HIV may contribute to cognitive impairment by damaging nerve cells, a new Johns Hopkins research suggests. …

Johns Hopkins study suggests the commonly prescribed anti-retroviral drug efavirenz attacks brain cells Read More »

HIV-associated fatigue in the era of highly active antiretroviral therapy: novel biological mechanisms?

I am convinced that our mitochondria are affected even after years off Zerit, DDI or AZT. Mitochondrial dysfunction has been widely reported with D drugs (D4T, DDI) and AZT and has been linked to lipoatrophy and metabolic problems.  But I think what we ignore is the permanent effects on the mitochondria even after years of stopping those drugs.   Although mitochondria DNA in fat and muscle …

HIV-associated fatigue in the era of highly active antiretroviral therapy: novel biological mechanisms? Read More »

FDA approved Jak inhibitors and their potential use in HIV – Interview with Dr Raymond Schinazi

As part of my work as a cure and salvage treatment activist, I am constantly searching for treatment options that could serve two purposes: existing medications that could help patients with multidrug resistance and at the same time be used as an approach to cure HIV.  Since my non profit (Program for Wellness Restoration) has …

FDA approved Jak inhibitors and their potential use in HIV – Interview with Dr Raymond Schinazi Read More »

Gilead Prices Its New STRIBILD Once a Day HIV Regimen Higher Than Complera and Atripla

Gilead has priced its STRIBILD at  $28,500 / year.  The other two single tablet HIV regimens, Complera and Atripla cost $26, 350 /year and $24,971.64/year, respectively. A regimen of twice a day raltegravir  (Isentress) plus once a day Truvada costs   $30,753 /year. Boosted Reyataz  plus Truvada  costs $34,390/year and boosted Prezista plus Truvada is …

Gilead Prices Its New STRIBILD Once a Day HIV Regimen Higher Than Complera and Atripla Read More »

Could Smart Drugs Help People With Cognitive Loss?

By Lily McCann Smart drugs, also known as neuro enhancers, memory enhancers, intelligence enhancers, cognitive enhancers and nootropics, are drugs and supplements that improve functions of the brain, including attention, memory, concentration and intelligence. These mental function enhancers are believed to work by improving the brain’s oxygen supply, stimulating the growth of nerves in the …

Could Smart Drugs Help People With Cognitive Loss? Read More »